Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jiac.2021.06.010 http://scihub22266oqcxt.onion/10.1016/j.jiac.2021.06.010 34176716!8196299!34176716     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Infect+Chemother 2021 ; 27 (9): 1350-1356 Nephropedia Template TP {{tp|p=34176716|t=2021. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort |pdf=|usr=}}{{34176716}} gab.com Text Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort JO: J Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=34176716 #FOAvip INTRODUCTION: Several clinical studies have reported the efficacy of favipiravir in reducing viral load and shortening the duration of symptoms. However, the viability of SARS-CoV-2 in the context of favipiravir therapy and the potential for resistance development is unclear. METHODS: We sequenced SARS-CoV-2 in nasopharyngeal specimens collected from patients who participated in a randomized clinical trial of favipiravir at hospitals across Japan between March and May 2020. Paired genomes were sequenced from those who remained RT-PCR-positive 5-8 days into favipiravir therapy. Daily nasopharyngeal specimens from 69 patients who were RT-PCR-positive at randomization were examined for a cytopathic effect (CPE). RESULTS: Some strains early in the trial belonged to clade 19 B, whereas the majority belonged to clade 20 B. The median time from the disease onset to negative CPE was 9 days. CPE was strongly correlated with the time from disease onset, viral load, age, and male sex. Among 23 patients for whom paired genomes were available, all except one had identical genomes. Two mutations were observed in one patient who received favipiravir, neither in the RdRp gene. CONCLUSIONS: The SARS-CoV-2 genome distribution in this clinical trial conducted in Japan reflected the early influx of strains from China followed by replacement by strains from Europe. CPE was significantly associated with age, male sex, and viral loads but not with favipiravir therapy. There was no evidence of resistance development during favipiravir therapy. Twit Text FOAVip Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort ????J Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=34176716 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34176716 #FOAvip English Wikipedia <ref>{{Cite pmid|34176716}}</ref> Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort #MMPMID34176716 Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T J Infect Chemother 2021[Sep]; 27 (9): 1350-1356 PMID34176716show ga INTRODUCTION: Several clinical studies have reported the efficacy of favipiravir in reducing viral load and shortening the duration of symptoms. However, the viability of SARS-CoV-2 in the context of favipiravir therapy and the potential for resistance development is unclear. METHODS: We sequenced SARS-CoV-2 in nasopharyngeal specimens collected from patients who participated in a randomized clinical trial of favipiravir at hospitals across Japan between March and May 2020. Paired genomes were sequenced from those who remained RT-PCR-positive 5-8 days into favipiravir therapy. Daily nasopharyngeal specimens from 69 patients who were RT-PCR-positive at randomization were examined for a cytopathic effect (CPE). RESULTS: Some strains early in the trial belonged to clade 19 B, whereas the majority belonged to clade 20 B. The median time from the disease onset to negative CPE was 9 days. CPE was strongly correlated with the time from disease onset, viral load, age, and male sex. Among 23 patients for whom paired genomes were available, all except one had identical genomes. Two mutations were observed in one patient who received favipiravir, neither in the RdRp gene. CONCLUSIONS: The SARS-CoV-2 genome distribution in this clinical trial conducted in Japan reflected the early influx of strains from China followed by replacement by strains from Europe. CPE was significantly associated with age, male sex, and viral loads but not with favipiravir therapy. There was no evidence of resistance development during favipiravir therapy. |*COVID-19[MESH] |*SARS-CoV-2[MESH] |Amides[MESH] |Antiviral Agents/therapeutic use[MESH] |China[MESH] |Europe[MESH] |Genomics[MESH] |Humans[MESH] |Japan[MESH] |Male[MESH] |Pyrazines[MESH]Virological and genomic analysis of SARS-CoV-2 from a favipiravir clin(epmc).pdf DeepDyve Pubget Overpricing